We introduce our pipeline.
I will explain biosimilars in an easy-to-understand manner.
Basic corporate data for FUJIFILM KYOWA KIRIN BIOLOGICS.
We will explain our strengths of handling biosimilars.
- Jun. 22, 2017
- Fujifilm Kyowa Kirin Biologics Presents Results from Randomized Phase 3 Study in Patient with Rheumatoid Arthritis, Demonstrating Clinical Equivalence of FKB327 with Adalimumab at 2017 EULAR (PDF: 142KB)
- May. 22, 2017
- Announces Marketing Authorisation Application for FKB327 Accepted for Review by European Medicines Agency (PDF: 57KB)
- Apr. 28, 2017
- The homepage was renewed.
- Mar. 3, 2017
- The UK High Court of Justice (Patents) Rules in Fujifilm Kyowa Kirin Biologics' Favor on Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Dosing Regimens for Adalimumab are Obvious and Unpatentable
- Oct. 19, 2016
- Fujifilm Kyowa Kirin Biologics Announces Positive Result in Primary Endpoint from Phase 3 Study of Adalimumab Biosimilar, anti-TNF- Monoclonal Antibody